What is Resverlogix Corp.?
, a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 25.86M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.